In conclusion, the data presented shows that ctDNA may be a dynamic and reliable tool for predicting and monitoring response to ICIs in patients with stage III/IV NSCLC in addition to PD-L1 expression levels with respect to both quantitative and qualitative data. Here, CD274 is linked to non-small cell lung carcinoma.